Primary navigation

    Adempas

    Drug - Adempas® (riociguat) [Bayer HealthCare Pharmaceuticals Inc.]

    March 2014

    Therapeutic area - Pulmonary arterial hypertension (PAH); Chronic thromboembolic pulmonary hypertension (CTEPH)

    Approval criteria

    • Patient has a diagnosis of PAH OR
    • Patient has a diagnosis of CTEPH

    Quantity limit

    Quantity limit = 102 tablets (all strengths).

    Background information

    Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with Pulmonary Arterial Hypertension (PAH) or Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

    Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top